SAN DIEGO--(BUSINESS WIRE)--Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given as a prophylactic or a treatment for SARS-CoV-2 infection, protects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback